New Jersey American Water Launches 2026 Flow Forward Summer Camp Program to Help Camden Teens Explore Water Industry Careers
Get Alerts AWK Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: +3.9%
Join SI Premium – FREE

Students from Free All Minds and Women of the Dream will participate in hands-on career exploration, workforce readiness and mentorship
The program will be hosted
Flow Forward is American Water's summer career exploration program designed to help high school sophomores, juniors and seniors learn more about the water and wastewater industry, gain practical experience and connect with employees who can share insights into career pathways across the company. Through the
During the camp, students will participate in sessions focused on communication skills, resume building, transferable skills, mock interview preparation and networking. They also will take part in breakout discussions with employees from across the business, tour the
"We are proud to welcome students from Free All Minds and Women of the Dream to Flow Forward here in
"
Flow Forward reflects New Jersey American Water's commitment to creating awareness of water industry careers, supporting local talent pipelines and helping
About New Jersey American Water
New Jersey American Water, a subsidiary of American Water (NYSE: AWK), is the largest regulated water utility in the state, providing safe, clean, reliable and affordable water and wastewater services to approximately 3 million people. For more information, visit www.newjerseyamwater.com and follow New Jersey American Water on LinkedIn, Facebook, X and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-jersey-american-water-launches-2026-flow-forward-summer-camp-program-to-help-camden-teens-explore-water-industry-careers-302822193.html
SOURCE American Water
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MaxsMaking Inc. Announces Receipt of Nasdaq Delisting Determination Notice
- Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
- Lyntris Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share